Showing 1531-1540 of 1774 results for "".
- Ciliatech to Present 36-Month Follow-Up Results on Intercil Uveal Spacer at Ophthalmology Futures European Forumhttps://modernod.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/Ciliatech has announced that it will reveal the combined 36-month follow-up results of its SAFARI I & II clinical trials at the Ophthalmology Futures European Forum on September 5. The company will share data on its Intercil Uveal Spacer, a Cilioscleral Interpositioning Device (CID) designed
- Researchers Detail How Neurons Build a 3-D Vascular Structure to Keep the Retina Healthyhttps://modernod.com/news/researchers-detail-how-neurons-build-a-3-d-vascular-structure-to-keep-the-retina-healthy/2482292/Scientists have known for years that a lattice of blood vessels nourishes cells in the retina that allow us to see – but it’s been a mystery how the intricate structure is created. Now, researchers at University of California San Francisco have found a new type of neuron that guides i
- Topcon Healthcare Partners with Microsoft to Deliver AI-Powered ‘Healthcare from the Eye’https://modernod.com/news/topcon-healthcare-partners-with-microsoft-to-deliver-ai-powered-healthcare-from-the-eye/2482274/Topcon Healthcare announced a partnership with Microsoft Corporation to deliver AI-powered ‘Healthcare from the Eye’ solutions to improve healthcare access, cost, and quality. A cloud-based connected network of healthcare providers using the 'Nuance Precision I
- BlueRock Therapeutics and Foundation Fighting Blindness Partner for IRD Studyhttps://modernod.com/news/bluerock-therapeutics-and-foundation-fighting-blindness-partner-for-ird-study/2482178/BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer, and Foundation Fighting Blindness announced a collaboration to add a new cohort to the Foundation’s 'Uni-Rare natural history study' of people living with inherited retinal diseases (I
- Aviceda Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Trial Assessing AVD-104 for GAhttps://modernod.com/news/aviceda-therapeutics-announces-first-patient-dosed-in-part-2-of-the-phase-23-siglec-trial-assessing-avd-104-for-ga/2482092/Aviceda Therapeutics announced it has dosed the first patient in part 2 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “Based on the efficacy and safety we saw in part 1, we moved rapidly to i
- Haag-Streit Launches New EyeSuite Softwarehttps://modernod.com/news/haag-streit-launches-new-eyesuite-software/2481532/Haag-Streit has announced the launch of EyeSuite software version i9.13, which offers new features for the Eyestar 900’s Anterior Chamber Suite and market-first functionality for the Lenstar Myopia. In addition, it’s existing portfolio of I
- Sight Sciences Appoints Ali Bauerlein as Chief Financial Officerhttps://modernod.com/news/sight-sciences-appoints-ali-bauerlein-as-chief-financial-officer/2481509/Sight Sciences announced the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. “I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive toward profitable growth
- Visus Therapeutics Appoints Eric D. Donnenfeld, MD, to Board of Directorshttps://modernod.com/news/visus-therapeutics-appoints-eric-d-donnenfeld-md-to-board-of-directors/2481347/Visus Therapeutics announced the appointment of Eric D. Donnenfeld, MD, to the company’s Board of Directors. Dr. Donnenfeld brings more than 30 years of clinical experience as an internationally recognized expert in refractive, cornea, and cataract surgery. “I am thrill
- Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosahttps://modernod.com/news/kiora-pharmaceuticals-doses-first-patient-in-abacus-phase-1b-study-evaluating-kio-301-for-retinitis-pigmentosa/2481248/Kiora Pharmaceuticals announced the dosing of the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with retinitis pigmentosa (RP). "We are thrilled the first patient has been treated and I'm very enc
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2481191/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Management. These orthokeratology (ortho-k) lenses are worn overnight for the control of myopia and are specifically designed to match a patient’s eye based on i